{"id":"W2167305078","doi":"10.1111/j.1365-2133.2012.11168.x","title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":336,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Janus kinase inhibitor; Medicine; Placebo; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Dose-ranging study; Internal medicine; Gastroenterology; Randomized controlled trial; Clinical endpoint; Dermatology; Double blind; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001212243,0.0002425595,0.001974065,0.000271451,0.0001190647,0.00001489576,0.0001877996,0.0001986466,0.00006895574],"category_scores_gemma":[0.000220371,0.0001746194,0.0003313888,0.0001514118,0.0002765612,0.0001953624,0.00001996045,0.000169592,0.000002654941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003116844,"about_ca_system_score_gemma":0.0000832758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001603472,"about_ca_topic_score_gemma":0.00009771683,"domain_scores_codex":[0.9948323,0.003192,0.001339614,0.0001655388,0.00008247451,0.0003880172],"domain_scores_gemma":[0.9976089,0.001284548,0.0007646217,0.0001829669,0.0001042092,0.00005477369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7124321,0.02612578,0.02240134,0.00003782601,0.004007525,0.00164961,0.0194988,0.000005336264,0.007326217,0.0001220084,0.00008861818,0.2063048],"study_design_scores_gemma":[0.9555706,0.002085418,0.01097865,0.0001122268,0.001740484,0.0156057,0.003769555,0.000003883652,0.009412089,0.00002633865,0.0005173137,0.000177686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696403,0.02810867,0.00002502476,0.00008263102,0.0005624724,0.00144788,0.00005601414,0.00000760184,0.00006944862],"genre_scores_gemma":[0.9980169,0.001683763,0.00008854909,0.00002103067,0.00006165983,0.00007027048,0.00002739338,0.00001381821,0.00001663241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2431385,"threshold_uncertainty_score":0.7120771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01880262927208139,"score_gpt":0.2817837546567371,"score_spread":0.2629811253846557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}